BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Diagnosis
17 results:

  • 1. Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.
    Jendželovský R; Jendželovská Z; Kuchárová B; Fedoročko P
    Biomed Pharmacother; 2019 Jan; 109():2173-2181. PubMed ID: 30551474
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical significance of the ABCB1 and abcg2 gene expression levels in acute lymphoblastic leukemia.
    Olarte Carrillo I; Ramos Peñafiel C; Miranda Peralta E; Rozen Fuller E; Kassack Ipiña JJ; Centeno Cruz F; Garrido Guerrero E; Collazo Jaloma J; Nacho Vargas K; Martínez Tovar A
    Hematology; 2017 Jun; 22(5):286-291. PubMed ID: 27960630
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. abcg2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid leukemia in Complete Remission.
    Damiani D; Tiribelli M; Geromin A; Cerno M; Zanini F; Michelutti A; Fanin R
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1621-1626. PubMed ID: 27178373
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. abcg2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.
    Damiani D; Tiribelli M; Geromin A; Michelutti A; Cavallin M; Sperotto A; Fanin R
    Am J Hematol; 2015 Sep; 90(9):784-9. PubMed ID: 26059733
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Reduced abcg2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
    de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
    Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2.
    Rahgozar S; Moafi A; Abedi M; Entezar-E-Ghaem M; Moshtaghian J; Ghaedi K; Esmaeili A; Montazeri F
    Cancer Biol Ther; 2014 Jan; 15(1):35-41. PubMed ID: 24145140
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Inactivation of PTEN increases abcg2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia.
    Huang FF; Wu DS; Zhang L; Yu YH; Yuan XY; Li WJ; Chen XP; Zhao XL; Chen FP; Zeng H
    Cancer Lett; 2013 Aug; 336(1):96-105. PubMed ID: 23603434
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death.
    Cortez MA; Scrideli CA; Yunes JA; Valera ET; Toledo SR; Pavoni-Ferreira PC; Lee ML; Petrilli AS; Brandalise SR; Tone LG
    Pediatr Blood Cancer; 2009 Dec; 53(6):996-1004. PubMed ID: 19672972
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Expression of MDR1, LRP, bcrp and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy.
    Fedasenka UU; Shman TV; Savitski VP; Belevcev MV
    Exp Oncol; 2008 Sep; 30(3):248-52. PubMed ID: 18806751
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (bcrp) genes and clinical outcome in childhood acute lymphoblastic leukemia.
    Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
    Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Drug resistance in childhood acute myeloid leukemia.
    Styczynski J
    Curr Pharm Biotechnol; 2007 Apr; 8(2):59-75. PubMed ID: 17430154
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Evaluation of bcrp and MDR-1 co-expression by quantitative molecular assessment in AML patients.
    Galimberti S; Guerrini F; Palumbo GA; Consoli U; Fazzi R; Morabito F; Santini V; Petrini M
    Leuk Res; 2004 Apr; 28(4):367-72. PubMed ID: 15109536
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Multidrug resistance in hematological malignancy.
    Hirose M; Hosoi E; Hamano S; Jalili A
    J Med Invest; 2003 Aug; 50(3-4):126-35. PubMed ID: 13678381
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
    van der Pol MA; Broxterman HJ; Pater JM; Feller N; van der Maas M; Weijers GW; Scheffer GL; Allen JD; Scheper RJ; van Loevezijn A; Ossenkoppele GJ; Schuurhuis GJ
    Haematologica; 2003 Feb; 88(2):134-47. PubMed ID: 12604403
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. bcrp gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia.
    Steinbach D; Sell W; Voigt A; Hermann J; Zintl F; Sauerbrey A
    Leukemia; 2002 Aug; 16(8):1443-7. PubMed ID: 12145683
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Increased expression of the breast cancer resistance protein (bcrp) in relapsed or refractory acute myeloid leukemia (AML).
    van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
    Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.
    van den Heuvel-Eibrink MM; Sonneveld P; Pieters R
    Int J Clin Pharmacol Ther; 2000 Mar; 38(3):94-110. PubMed ID: 10739113
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.